Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.
Authors: Guglielmetti L; Médecins Sans Frontières, Paris, France; Department of Infectious, Tropical Diseases and Microbiology, IRCCS Sacro Cuore Don Calabria Hospital, Verona, Italy. Electronic address: lorenzo.guglielmetti@paris.msf.org., Khan U; Interactive Research and Development Global, Singapore; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University Montreal, Montreal, QC, Canada., Velásquez GE; Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, CA, USA; Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, CA, USA., Gouillou M; Epicentre, Paris, France., Ali MH; Interactive Research and Development, Karachi, Pakistan., Amjad S; Interactive Research and Development, Karachi, Pakistan., Kamal F; Interactive Research and Development, Karachi, Pakistan., Abubakirov A; National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan., Ardizzoni E; Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Baudin E; Epicentre, Paris, France., Bektassov S; National Scientific Center of Phthisiopulmonology, Almaty, Kazakhstan., Berry C; Médecins Sans Frontières, London, UK., Bonnet M; Translational Research on HIV and Endemic and Emerging Infectious Diseases, Montpellier Université de Montpellier, Institut de Recherche pour le Développement, INSERM, Montpellier, France., Chavan V; Médecins Sans Frontières, Mumbai, India., Coutisson S; Médecins Sans Frontières, Geneva, Switzerland., Dakenova Z; City Center of Phthisiopulmonology, Astana, Kazakhstan., de Jong BC; Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Dinh LV; National Lung Hospital, Hanoi, Viet Nam., Ferlazzo G; Médecins Sans Frontières, Geneva, Switzerland., Kirakosyan O; Department of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany., Lachenal N; Médecins Sans Frontières, Geneva, Switzerland., Lecca L; Socios en Salud-Sucursal, San Isidro, Peru; Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA., McIlleron H; Department of Medicine, University of Cape Town, Cape Town, South Africa., Mikanda KK; Partners In Health Lesotho, Maseru, Lesotho., Mucching-Toscano S; Socios en Salud-Sucursal, San Isidro, Peru., Mulders W; Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Mushtaque H; The Indus Hospital and Health Network, Karachi, Pakistan., Nahid P; Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, CA, USA., Nguyen DV; Hanoi Lung Hospital, Hanoi, Viet Nam., Nguyen NV; National Lung Hospital, Hanoi, Viet Nam., Oyewusi L; Partners In Health Lesotho, Maseru, Lesotho., Motta I; MRC Clinical Trials Unit, UCL, London, UK; Médecins Sans Frontières, Geneva, Switzerland., Panda S; Indian Council of Medical Research, New Delhi, India., Patil S; National AIDS Research Institute, Pune, India., Pham TH; Hanoi Lung Hospital, Hanoi, Viet Nam., Phan DT; Pham Ngoc Thach Hospital, Ho Chi Minh City, Viet Nam., Phan HTT; Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, CA, USA; Hanoi Lung Hospital, Hanoi, Viet Nam; Vietnam National TB Program University of California San Francisco Research Collaboration Unit, Center for Promotion of Advancement of Society Hanoi, Hanoi, Viet Nam., Phillips PPJ; Center for Tuberculosis, Institute for Global Health Sciences, University of California, San Francisco, CA, USA., Ruiz J; Socios en Salud-Sucursal, San Isidro, Peru., Rupasinghe P; Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium., Salahuddin N; The Indus Hospital and Health Network, Karachi, Pakistan., Sanchez-Garavito E; Socios en Salud-Sucursal, San Isidro, Peru; Hospital Nacional Sergio E Bernales, Comas, Peru., Seung KJ; Division of Global Health Equity, Brigham and Women's Hospital, MA, USA., Asfaw MT; Partners In Health Lesotho, Maseru, Lesotho., Vargas Vasquez D; Hospital Nacional Hipólito Unanue, El Agustino, Peru; Socios en Salud-Sucursal, San Isidro, Peru., Rich ML; Partners In Health, Boston, MA, USA; Division of Global Health Equity, Brigham and Women's Hospital, MA, USA., Varaine F; Médecins Sans Frontières, Paris, France., Mitnick CD; Partners In Health, Boston, MA, USA; Division of Global Health Equity, Brigham and Women's Hospital, MA, USA; Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Corporate Authors: endTB-Q Clinical Trial Team
Source: The Lancet. Respiratory medicine [Lancet Respir Med] 2025 Sep; Vol. 13 (9), pp. 809-820. Date of Electronic Publication: 2025 Jul 16.
Publication Type: Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 101605555 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-2619 (Electronic) Linking ISSN: 22132600 NLM ISO Abbreviation: Lancet Respir Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-2619
DOI:10.1016/S2213-2600(25)00194-8